Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers |
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer | Phase1 | Canada Israel Switzerland United States View All |
NCT06562192 |
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France |
Multiple Sclerosis (MS) | France | NCT06157086 | |
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study |
Sickle Cell Disease | Phase4 | Belgium Colombia Germany Italy Lebanon Oman Spain Turkey United States View All |
NCT04657822 |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Austria Brazil Bulgaria Canada China Czechia Denmark France Germany Italy Korea, Republic of Malaysia Mexico Poland Portugal Romania Russian Federation Spain Turkey United Kingdom United States View All |
NCT04877522 |
Asciminib RMP Study |
Chronic Myeloid Leukemia | Korea, Republic of | NCT05943522 | |
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea |
Non-Small-Cell Lung Carcinoma | Korea, Republic of | NCT05703516 | |
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase3 | Australia Austria Belgium Canada Denmark Finland France Germany Israel Italy Japan Norway Singapore Spain Taiwan United Kingdom United States View All |
NCT02445222 |
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. |
Non-Small Cell Lung Carcinoma | Phase4 | India | NCT05110196 |
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
Extensive Stage Small Cell Lung Cancer | Phase1, Phase2 | Canada France Germany Israel Singapore Spain United Kingdom United States View All |
NCT05142696 |
Special Drug Use-results Surveillance of Tafinlar/Mekinist |
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor | Japan | NCT06262919 |